Peripheral Arterial Volume: A New Frontier in Cardiovascular Risk Assessment
"Unlock the potential of PAV in predicting coronary artery disease and improving patient outcomes."
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, driving ongoing research into improved methods for early detection and risk stratification. Endothelial dysfunction, a key early event in the development of atherosclerosis, has emerged as a critical target for novel diagnostic and therapeutic strategies.
Traditional methods of assessing cardiovascular risk, such as the Framingham Risk Score (FRS), rely on conventional risk factors like age, cholesterol levels, and blood pressure. While these tools have proven valuable, they often fail to identify individuals at risk who do not exhibit these classic risk factors. This limitation has fueled the search for more sensitive and specific markers of early vascular disease.
A new technique, fingertip reactive hyperemia peripheral arterial volume (PAV) has emerged as a potential tool for improved risk stratification. This article explores the science behind PAV, its clinical applications, and the potential benefits it offers over traditional risk assessment methods in predicting coronary artery disease (CAD).
Why Peripheral Arterial Volume Matters
Peripheral arterial volume may offer a useful lens for understanding vascular function and cardiovascular risk. Its clinical significance is likely to depend on how consistently it can be measured and interpreted alongside established risk factors. Because evidence and implementation are still developing, its broader impact should be described cautiously rather than as a settled clinical standard.
Current Assessment Methods
Clinicians currently rely on established vascular examinations and diagnostic tests to assess peripheral arterial disease and related risk. These methods can provide valuable information, but no single measurement captures every aspect of vascular health. Peripheral arterial volume may therefore be best considered a complementary measure until stronger evidence defines its independent diagnostic and prognostic value.
The 1972 PVR Milestone
Pulse volume recording (PVR) was introduced in 1972 and became an integral part of vascular laboratory diagnostic testing. PVR measurements are often the first vascular test performed in patients suspected of having peripheral arterial disease in the upper or lower extremities. Lower-limb PVRs provide indirect physiologic information about arterial and venous hemodynamics, and multiple medical-device manufacturers later developed PVR instrumentation.
What is Peripheral Arterial Volume (PAV)?
Peripheral Arterial Volume (PAV) is a non-invasive method used to assess endothelial function by measuring changes in pulsatile blood flow volume in the fingertips during reactive hyperemia. Reactive hyperemia is the temporary increase in blood flow that occurs after a period of ischemia (restricted blood supply).
- Non-invasive: PAV is a non-invasive procedure, making it safe and comfortable for patients.
- Easy to administer: The test is simple to perform, requiring minimal training and equipment.
- Provides real-time data: PAV provides immediate feedback on endothelial function, allowing for timely intervention.
An Expanding Evidence Base
Recent coverage and reviews continue to examine peripheral vascular disease as a condition involving blood vessels outside the heart, including vessels in the legs and arms. The 2025 Nature Reviews Disease Primers article by Aboyans and colleagues reviews peripheral artery disease epidemiology, pathophysiology, diagnosis, management, and future research needs. A separate comprehensive updated review addresses the disease's clinical course, diagnosis, and medical and interventional management, while JAMA's 2026 collection highlights diagnosis, prevention, management, and risk factors.
Evidence Still Has Boundaries
Peripheral arterial volume should not yet be treated as a definitive replacement for established vascular assessment. Its usefulness may vary with measurement technique, patient characteristics, and clinical setting. Further validation is needed before it can support broad claims about cardiovascular risk, treatment selection, or patient outcomes.
A Complementary Perspective
Peripheral arterial volume represents a different potential perspective on vascular health than conventional clinical assessments. Comparisons should focus on whether it adds reproducible information beyond existing tests rather than assuming that a new measurement is automatically superior. At present, the most defensible interpretation is that it may complement, rather than displace, accepted methods.
The Future of Cardiovascular Risk Assessment with PAV
Peripheral Arterial Volume (PAV) holds significant promise as a valuable tool for improving cardiovascular risk assessment. By providing a direct measure of endothelial function, PAV can help identify individuals at risk of CAD who may be missed by traditional risk factors.
From Measurement to Better Care
A 2024 multidisciplinary roundtable identified knowledge gaps in lower-extremity revascularization and considered how intravascular ultrasound (IVUS) might improve care and outcomes for peripheral arterial and deep venous disease. The 2024 multisociety guideline describes peripheral artery disease as associated with amputation, myocardial infarction, stroke, death, impaired quality of life, reduced walking performance, and impaired functional status. Commentary from the American College of Cardiology notes that the case for IVUS in peripheral endovascular arterial and venous interventions is building, although the cited evidence includes observational and randomized PCI data rather than proof that every peripheral application produces the same benefit.
Forecasting Need and Opportunity
Research using the Global Burden of Disease 2021 database is analyzing global lower-extremity peripheral arterial disease incidence from 1990 through 2021 and forecasting trends from 2022 to 2030. That work is intended to inform healthcare planning and resource allocation. Commercial forecasts also point to expanding interest: one report projects the peripheral artery disease market to grow from $5.82 billion in 2026 to $10.31 billion by 2034, at a 7.41% CAGR, while another describes continuous double-digit regional growth pockets in emerging economies through 2035 as screening infrastructure and reimbursement improve.
Implementation Beyond the Device
The broader value of peripheral arterial volume will depend on more than measurement technology alone. Clinical adoption may require consistent protocols, meaningful interpretation, appropriate follow-up, and equitable access to vascular evaluation. These practical requirements make implementation and health-system coordination as important as technical development.
Outcomes in Practice
An analysis of patients undergoing peripheral vascular intervention found that the highest-volume operators were associated with lower incidences of in-hospital major adverse limb events and major adverse cardiac events. A Reflow Medical case study describes a 77-year-old man with peripheral arterial disease, critical limb-threatening ischemia, paroxysmal atrial fibrillation, type II diabetes, hypertension, hyperlipidemia, and a history of smoking. Together, these reports illustrate how procedural expertise and complex patient profiles can shape the real-world consequences of peripheral vascular disease.
The study showed that incorporating PAV into the Framingham Risk Score (FRS) improved the prediction of CAD, increasing the C statistic and the net reclassification index (NRI). This suggests that PAV provides additional clinical value beyond traditional risk factors.
While further research is needed to fully elucidate the clinical utility of PAV, current evidence suggests that PAV may be a useful method for identifying patients at high risk for CAD, allowing for earlier intervention and improved outcomes.